Global Autologous Stem Cell & Non-stem Cell Therapies Market Growth (Status and Outlook) 2024-2030

Global Autologous Stem Cell & Non-stem Cell Therapies Market Growth (Status and Outlook) 2024-2030

Autologous stem cell and non-stem cell therapies involve using a patient’s own cells to treat various medical conditions, offering personalized treatment options that minimize the risk of immune rejection and other complications.

The global Autologous Stem Cell & Non-stem Cell Therapies market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.

LPI (LP Information)' newest research report, the “Autologous Stem Cell & Non-stem Cell Therapies Industry Forecast” looks at past sales and reviews total world Autologous Stem Cell & Non-stem Cell Therapies sales in 2022, providing a comprehensive analysis by region and market sector of projected Autologous Stem Cell & Non-stem Cell Therapies sales for 2023 through 2029. With Autologous Stem Cell & Non-stem Cell Therapies sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Autologous Stem Cell & Non-stem Cell Therapies industry.

This Insight Report provides a comprehensive analysis of the global Autologous Stem Cell & Non-stem Cell Therapies landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Autologous Stem Cell & Non-stem Cell Therapies portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Autologous Stem Cell & Non-stem Cell Therapies market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Autologous Stem Cell & Non-stem Cell Therapies and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Autologous Stem Cell & Non-stem Cell Therapies.

United States market for Autologous Stem Cell & Non-stem Cell Therapies is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Autologous Stem Cell & Non-stem Cell Therapies is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Autologous Stem Cell & Non-stem Cell Therapies is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Autologous Stem Cell & Non-stem Cell Therapies players cover Anterogen Co., Ltd., APAC Biotech, Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited, Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Autologous Stem Cell & Non-stem Cell Therapies market by product type, application, key players and key regions and countries.

Segmentation by Type:
CAR-T
Tumor Infiltrating Lymphocyte

Segmentation by Application:
Hospital
Surgery Center
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

Segmentation by Type:
CAR-T
Tumor Infiltrating Lymphocyte

Segmentation by Application:
Hospital
Surgery Center
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Anterogen Co., Ltd.
APAC Biotech
Bristol-Myers Squibb Company
CARsgen Therapeutics Holdings Limited
Dendreon Pharmaceuticals LLC (Sanpower Group Co., Ltd.)
Gilead Sciences, Inc.
Green Cross Holdings Co., Ltd. (GC Cell)
Healiva SA
ImmunoACT
Iaso Biotherapeutics
Johnson & Johnson
Lovance Biotherapeutics, Inc.
Novartis AG
Pharmicell Co., Ltd.
Regrow Biosciences Pvt Ltd.
Tegoscience
Vericel Corporation
W (Cayman) Therapeutics Co. Ltd.

Please note: The report will take approximately 2 business days to prepare and deliver.